Biota Pharmaceuticals to Host Conference Call to Report First Quarter Fiscal Year 2016 Financial Results on November 6, 2015

ATLANTA, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, November 6, 2015 at 9:00 a.m. ET to review the Company's financial results for the three month period ended September 30, 2015 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.

In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 55857667. The live webcast can be accessed under the Investors section of the Company's website at www.biotapharma.com or you may use the link:


About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in clinical development that address viral infections that have limited therapeutic options. Vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, is currently being evaluated in the Company's ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion (F) protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections; and a preclinical stage RSV non-fusion inhibitor program that complements our F-protein inhibitor BTA585.For additional information about the Company, please visit www.biotapharma.com.

CONTACT: Joseph M. Patti, PhD President and Chief Executive Officer (678) 221-3352 j.patti@biotapharma.com Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200 sarah@sternir.com

Source:Biota Pharmaceuticals, Inc.